Dechra Pharmaceuticals PLC Grant of award - Deferred Bonus Plan (0415A)
20 Septiembre 2022 - 10:44AM
UK Regulatory
TIDMDPH
RNS Number : 0415A
Dechra Pharmaceuticals PLC
20 September 2022
20 September 2022
Dechra Pharmaceuticals PLC
(the Company)
LEI: 213800J4UVB5OWG8VX82
Notification and public disclosure of transactions by persons
discharging managerial responsibilities (PDMRs)
The Company announces that on 20 September 2022 the following
Directors were granted awards over Ordinary Shares of 1 pence each
in the Company under the Dechra 2021 Deferred Bonus Plan:
Name of individual Director Type of award Number of shares
subject to award
DBP Award -
Ian Page Director nil cost option 3,580
---------- ------------------ ------------------
DBP Award -
Paul Sandland Director nil cost option 2,293
---------- ------------------ ------------------
DBP Award -
conditional
Tony Griffin Director award 1,655
---------- ------------------ ------------------
In accordance with the Directors' Remuneration Policy, 20% of
the annual bonus earned in respect of the Company's 2022 financial
year has been deferred into a share award. The awards will vest at
the end of a deferral period of two years.
The Notification of Dealing Forms set out below are provided in
accordance with the requirements of the Market Abuse
Regulation.
Notification of Dealing Form
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Ian Page
----------------------------- ------------------------------------
2. Reason for the notification
-------------------------------------------------------------------
a) Position/status Director
----------------------------- ------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- ------------------------------------
3. Details of the Issuer
-------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
----------------------------- ------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
----------------------------- ------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
-------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial
instrument ISIN: GB0009633180
Identification
code
----------------------------- ------------------------------------
b) Nature of the Grant of award over Ordinary Shares
transaction under the Company's Deferred Bonus
Plan
----------------------------- ------------------------------------
c) Price(s) and volumes(s) Price Volume
Nil cost award 3,580
-------
----------------------------- ------------------------------------
d) Aggregated information
* Aggregate volume
N/A
* Price
----------------------------- ------------------------------------
e) Date of the transaction 2022-09-20
----------------------------- ------------------------------------
f) Place of the transaction Outside a trading venue
----------------------------- ------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Paul Sandland
----------------------------- ------------------------------------
2. Reason for the notification
-------------------------------------------------------------------
a) Position/status Director
----------------------------- ------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- ------------------------------------
3. Details of the Issuer
-------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
----------------------------- ------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
----------------------------- ------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
-------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial
instrument ISIN: GB0009633180
Identification
code
----------------------------- ------------------------------------
b) Nature of the Grant of award over Ordinary Shares
transaction under the Company's Deferred Bonus
Plan
----------------------------- ------------------------------------
c) Price(s) and volumes(s) Price Volume
Nil cost award 2,293
-------
----------------------------- ------------------------------------
d) Aggregated information
* Aggregate volume
N/A
* Price
----------------------------- ------------------------------------
e) Date of the transaction 2022-09-20
----------------------------- ------------------------------------
f) Place of the transaction Outside a trading venue
----------------------------- ------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Tony Griffin
----------------------------- ------------------------------------
2. Reason for the notification
-------------------------------------------------------------------
a) Position/status Director
----------------------------- ------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- ------------------------------------
3. Details of the Issuer
-------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
----------------------------- ------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
----------------------------- ------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
-------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial
instrument ISIN: GB0009633180
Identification
code
----------------------------- ------------------------------------
b) Nature of the Grant of award over Ordinary Shares
transaction under the Company's Deferred Bonus
Plan
----------------------------- ------------------------------------
c) Price(s) and volumes(s) Price Volume
Nil cost award 1,655
-------
----------------------------- ------------------------------------
d) Aggregated information
* Aggregate volume
N/A
* Price
----------------------------- ------------------------------------
e) Date of the transaction 2022-09-20
----------------------------- ------------------------------------
f) Place of the transaction Outside a trading venue
----------------------------- ------------------------------------
For further information, please contact:
Melanie Hall, Company Secretary
Telephone: 01606 814730
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and
related products business. Our expertise is in the development,
manufacture, and sales and marketing of high quality products
exclusively for veterinarians worldwide. For more information
please visit: www.dechra.com .
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of
Dechra Pharm aceuticals PLC.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHPPUWCBUPPGAU
(END) Dow Jones Newswires
September 20, 2022 11:44 ET (15:44 GMT)
Dechra Pharmaceuticals (LSE:DPH)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Dechra Pharmaceuticals (LSE:DPH)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024